Casey C. Lynch has served as our President and Chief Executive Officer and a member of our board of directors since July 2014, and as Chairman of our board of directors since November 2018. Prior to co-founding Cortexyme, Ms. Lynch co-founded and led various companies and organizations in the biotechnology industry including Aspira Biosystems, Inc. and NeuroInsights, LLC. She served as Aspira’s co-founder, President and Chief Executive Officer from 1999 to 2004 and she co-founded NeuroInsights, LLC and served as its Managing Director from 2004 to 2015. Ms. Lynch also co-founded the Neurotechnology Industry Organization and served as a board member from March 2005 to September 2018. Ms. Lynch oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals, including multiple sclerosis, arthritis, and uveitis. Ms. Lynch conducted preclinical testing for Alzheimer’s disease treatment at the Wadsworth Medical Center and researched the neurological basis of schizophrenia and epilepsy at UCLA. Her graduate work on neurotrophic factor cell biology and neurodegenerative diseases, was carried out at UCSF and Stanford University. Ms. Lynch holds a B.S. in Neuroscience from the University of California, Los Angeles, an M.S. in Neuroscience from the University of California, San Francisco.
Prior to joining Cortexyme, Mr. Monohon served as Chief Financial Officer at X10 Capital, a private equity firm, from March 2017 to December 2018 and he served as Chief Financial Officer and Vice President of Finance at Fantex, Inc. from July 2012 to March 2017. Mr. Monohon holds a B.S. in Accounting from Rochester Institute of Technology.
To this position, she brings 25 years of corporate affairs expertise garnered from corporate and strategic consulting roles with experience that spans varied industries, including biotech, pharmaceutical, medical device, technology, energy, media, and restaurant, among others. Ms. Roughan’s core skill set centers around strategic storytelling and crafting a narrative that is differentiated and competitively compelling to provide breakthrough communications results. She also possesses extensive experience operating in complex and highly regulated businesses, including compliance with Food and Drug Administration drug discovery processes, phased clinical trials, and drug commercialization efforts, patented technologies, corporate litigation, emerging environmental, social, and governance matters, in addition to Securities and Exchange Commission regulations.
She holds a B.A. in English and Comparative Literary Studies, with a minor in Geology, from Occidental College.
Board of Directors
David A. Lamond joined our board of directors in 2015. Since April 2016, Mr. Lamond has served as president of En Pointe LLC, an investment firm. From 2011 to 2016, he served as the president, chief executive officer and chief investment officer of Lamond Capital Partners LLC. Mr. Lamond also is currently a member of the board of directors of Applied Molecular Transport (AMTI), a biopharmaceutical company, and previously served on the board of Arrinex, a medical device company. In addition, Mr. Lamond is on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.
Una Ryan, OBE, Ph.D. joins the board with a deep background in the biopharma space, including extensive experience serving on the boards of public, private and non-profit companies. She is currently an investor including as a managing director of Golden Seeds and as a partner in Astia Angel. Previously, she served as president and CEO of AVANT Immunotherapeutics, a company developing vaccines and Immunotherapeutics for cancer and broader health applications; Diagnostics for All; and Celldex Therapeutics. As a scientist, Dr. Ryan is credited with the localization of angiotensin converting enzyme as a target that led to the development of an important class of blood pressure medicines. In 2002 Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for services to biotechnology. She subsequently received the Albert Einstein Award for outstanding achievement in the life sciences in 2007, as well as the Cartier Women’s Initiative Award in 2009. Dr. Ryan obtained her undergraduate degree from the University of Bristol and her Ph.D. from the University of Cambridge.
Stephen S. Dominy, M.D., has served as a member of our board of directors since December 2015 and as our Chief Scientific Officer since April 2016. Prior to co-founding Cortexyme, Dr. Dominy served as a Division Director at San Francisco General Hospital and as Associate Professor of Psychiatry at the University of California, San Francisco School of Medicine from 2006 to 2016. Dr. Dominy holds a B.S. in Pharmacy from The Ohio State University College of Pharmacy and an M.D. from the Wright State University Boonshoft School of Medicine.
Margaret (Margi) McLoughlin, Ph.D., is an independent director. Until April of 2019, Margi worked in Pfizer’s Worldwide Business Development (WWBD) organization and Pfizer Ventures where she was a Partner in Pfizer Ventures and an Executive Director in WWBD. In this role, Margi served on the boards of 4D Molecular Therapeutics, Adapsyn, BioAtla, System1, and Cortexyme with a focus on making investments and working with companies to help advance products and technologies of value to the pharmaceutical industry. After joining Pfizer in 2001, she worked in roles of increasing responsibility in WWBD, played a significant role in defining Pfizer’s Centers for Therapeutic Innovation, in addition to leading transactions with multiple biotech companies, including Ablexis, Gliknik, and Excaliard, among others. Margi also held a position in Discovery Research at Mallinckrodt Medical developing diagnostic pharmaceuticals for nuclear medicine, MR, and X-ray imaging. After five years in the laboratory, she spent two years in Technology Planning at Mallinckrodt Medical where she supported internal R&D through outside alliances. Additionally, Margi served as Associate Director in the Office of Cooperative Research at Yale University. She received her B.S. in Chemistry from University of California, Irvine and her Ph.D. in Chemistry from University of California, Santa Barbara.
Chris Senner has nearly three decades of finance experience at industry-leading biotechnology and pharmaceutical companies. He currently serves as Executive Vice President and Chief Financial Officer of Exelixis, Inc. (EXEL), a commercially successful, oncology-focused biotech advancing medicines for difficult-to-treat cancers. At Exelixis, Mr. Senner leads a team responsible for providing the financial infrastructure for the company’s growing commercial oncology franchise, broad clinical development operations, and reinitiated drug discovery activities. Before joining Exelixis, Mr. Senner served for five years as Vice President, Corporate Finance at Gilead Sciences. Prior to Gilead, he spent eighteen years at Wyeth, including as CFO of its U.S. pharmaceuticals business and BioPharma Business Unit. Mr. Senner holds a B.S. in Finance from Bentley College.
Clinical Advisory Board
Dr. Mark Brody is President and Founder of Brain Matters Research, one of the largest private clinical research facilities in the country specializing in Alzheimer’s Disease diagnosis, treatment and research. He is a nationally recognized expert in both Alzheimer’s Disease and stroke, as well as the Principal Investigator in numerous clinical trials seeking to prevent and treat Alzheimer’s. He is in private practice in Delray Beach specializing in memory disorders and stroke prevention. He is one of a small group of neurologists whose career spans an academic practice, clinical practice, as well as clinical research. A former Professor of Neurology at University of California, San Diego, and Stroke Program Director at Scipps, La Jolla, he eventually relocated to Palm Beach County in 1995. He was the founding Director of the Acute Interventional Stroke Program at Bethesda Memorial Hospital, where he and his team conducted acute stroke clinical trials seeking to optimize the “time-to-treatment” and outcomes for stroke victims.
Martin Farlow, MD | Professor Emeritus, University of Indiana & co-director of the Alzheimer’s Disease Center at Indiana University
Dr. Farlow is Professor of Neurology and Vice-Chairman of Research in the Department of Neurology at the Indiana University School of Medicine in Indianapolis. He is also Associate Co-Director of the Indiana Alzheimer’s Disease Center in Indianapolis and leads a large Alzheimer and related dementias clinical trials site in the Department of Neurology and has led and/or contributed in various ways to over 150 clinical trials over the last 25 years. Dr. Farlow received his medical degree from Indiana University School of Medicine and completed an internship in medicine and residency in neurology at the Indiana University Hospitals. Dr. Farlow is a member of many professional associations including AAN, ANA and AGS. He is also a founding member in both the American Society of Experimental Neurotherapeutics and the International Society for CNS Clinical Trials and Methodology. Dr. Farlow has lectured on the topics of aging, dementia, and Alzheimer’s disease at more than 300 meetings, conferences, and hospitals/medical schools throughout the world. He is a reviewer for numerous scientific journals and on the editorial boards of MedLink and Current Alzheimer Research.
David Munoz, MD | Head of Pathology at St. Michael’s Hospital, Toronto, and Professor at University of Toronto
Dr. David Munoz holds an MD from Navarre and MSc in Pathology from Queen’s University, Ontario. He trained in neurology and neuropathology and became a Fellow of the Royal College of Physicians and Surgeons of Canada in 1984. He has practiced in Vermont, Saskatoon, London (ON), Madrid, and Toronto, and briefly in Vancouver. He is currently a Neuropathologist and Head, Division of Pathology at St. Michael’s Hospital, Toronto, and Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto. He is the author of 194 peer-reviewed papers, 20 book chapters, and co-author of one book. He has held research grants in Canada (Medical Research Council and Canadian Institutes of Health Reasearch) and USA (National Institutes of Health). His research interest is focused on neuropathology, particularly the mechanisms of development and progression of degenerative diseases of the brain, including Alzheimer’s disease, the non-Alzheimer dementias, movement disorders, and amyotrophic lateral sclerosis. His other research interest in neurooncology is derived from his clinical practice.
Marwan Sabbagh, MD | Professor of Neurology, Alzheimer's and Memory Disorders Division, Barrow Neurological Institute
Marwan Noel Sabbagh, MD, board certified neurologist and geriatric neurologist, is considered one of the leading experts in Alzheimer’s and dementia. He is Professor of Neurology at the Alzheimer’s and Memory Disorders Division of the Barrow Neurological Institute at Dignity Health/St Joseph’s Hospital and Medical Center in Phoenix, Arizona. Dr. Sabbagh has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases. He is a leading investigator for many prominent national Alzheimer’s prevention and treatment trials. Dr. Sabbagh is on the editorial board for Journal of Alzheimer’s Disease and BMC Neurology. He is now editor in chief of Neurology and Therapy. He has authored and co-authored almost 370 medical and scientific articles on Alzheimer’s research. Dr. Sabbagh is the author of The Alzheimer’s Answer: Reduce Your Risk and Keep Your Brain Healthy, with foreword by Justice Sandra Day O’Connor, and of The Alzheimer’s Prevention Cookbook: 100 Recipes to Boost Brain Health. He has edited Palliative Care for Advanced Alzheimer’s and Dementia: Guidelines and Standards for Evidence Based Care and Geriatric Neurology, published in 2014 and Fighting for my Life: living in the shadow of Alzheimer’s disease in 2019. Dr. Sabbagh has been recognized with numerous awards, including WestMarc Innovator Award, 2015; Fellow of the American Academy of Neurology, 2004. He earned his undergraduate degree from the University of California, Berkeley and his medical degree from the University of Arizona in Tucson. He received his residency training in neurology at Baylor College of Medicine, Houston, Texas, and completed his fellowship in geriatric neurology and dementia at the University of California, San Diego School of Medicine, where he served on the faculty as assistant professor. Prior to his current position, Dr. Sabbagh was the Camille and Larry Ruvo Endowed Chair for Brain Health and Director of Translational Research at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Before joining the faculty of the Cleveland Clinic, he was at the Barrow Neurological Institute where he served for three years, and prior to that, he was the director of the Banner Sun Health Research Institute for 15 years.
Mercè Boada, MD, PhD | Professor, Chief Medical Officer, Fundació ACE. Barcelona Alzheimer Treatment and Research Center, Universitat International de Catalunya-Barcelona
Dr. Mercè Boada is founder and medical director of Fundació ACE, Institute Català de Nuerosciènces Aplicades. Dr. Mercè earned her PhD in Medicine from the Autonomous University of Barcelona and neurology specialist. Until 2013 she was responsible for Neurodegenerative Diseases unit at the Neurology Service, University Hospital Vall d’Hebron, Head of the research group “Alzheimer” at the Vall d’Hebron Research Institute in Barcelona Spain.
Jeffrey Cummings, MD| Emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and Director of Center for Neurodegeneration and Translational Neuroscience
Dr. Jeffrey Cummings is Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic; he is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada and Cleveland, Ohio. Dr. Cummings has expertise in neuropsychiatric assessment, outcomes in clinical trials, clinical trial design and analysis and global clinical trials. He is a frequent consultant to industry. He has authored more than 500 peer-reviewed papers and 30 books on Alzheimer’s disease, neuropsychiatry, and clinical trials. Dr. Jeffrey Cummings is a member of the Alzheimer’s Disease Cooperative Study (ADCS), the NINDS Neuroprotection in Parkinson’s Disease (NET-PD) oversight committee, American College of Neuropsychopharmacology, American Society for Experimental Neurotherapeutics, American Academy of Neurology, American Neurologic Association, American Neuropsychiatric Association (past president), Behavioral Neurology Society (past president), and American Association of Geriatric Psychiatry (honorary member), among many prestigious organizations. Dr. Jeffrey Cummings graduated magna cum laude from the University of Wyoming, Laramie and obtained his MD degree (with thesis) from the University of Washington, Seattle. He completed internship at Hartford Hospital in Hartford, Connecticut and did his Neurology residency at Boston University, Boston, Massachusetts. Dr. Jeffrey Cummings had his specialty training in Behavioral Neurology at Boston University and pursued advanced studies in Neuropsychiatry and Neuropathology at the National Hospital for Nervous Diseases, Queen Square, London.
Dr. Thomas Laughren currently serves as the director of Laughren Psychopharm Consulting, LLC. He is retired as Division Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research, at FDA (Silver Spring, MD). Prior to coming to FDA in September 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine, also in Providence. Dr. Laughren received his medical degree from the University of Wisconsin–Madison, and he also completed residency training in psychiatry at the University of Wisconsin. Dr. Laughren is board certified in general psychiatry. As Division Director for the Division of Psychiatry Products, Dr. Laughren oversaw the review of all psychiatric drug development activities conducted under INDs and the review of all NDAs and supplements for new psychiatric drug claims. He has authored or coauthored many papers and book chapters on regulatory and methodological issues pertaining to the development of psychiatric drugs and is a frequent speaker at professional meetings on these same topics. Dr. Laughren has received numerous awards for his regulatory accomplishments.
Mark Ryder, DMD is Professor and Chair of Orofacial Sciences at the University of California, San Francisco School of Dentistry. Dr. Ryder received his DMD from Harvard School of Dental Medicine.
Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer’s Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health’s CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer’s disease.
Pierre N. Tariot, MD is Banner Alzheimer’s Institute director and also University of Arizona College of Medicine research professor. Dr. Tariot has investigated and lectured extensively on multiple aspects of diagnosis, therapy and prevention of Alzheimer’s disease and has published more than 350 papers on these topics. He has served as an author for several studies that have led to Food & Drug Administration (FDA) approval of treatments for Alzheimer’s disease. Dr. Tariot has led efforts to refine how behavioral changes in dementia are measured. He has contributed to large multicenter trials of a range of treatments for these neuropsychiatric features. Alongside his colleagues Dr. Tariot leads the Alzheimer’s Prevention Initiative, which is credited with helping launch a new era in Alzheimer’s prevention research. Dr. Tariot also leads the Banner Dementia Care Partners, a program designed to demonstrate the clinical and cost-effectiveness of standardized care for persons with dementia in a large health care system. He is a member of the American College of Neuropsychopharmacology.
Clive Holmes, PhD | Professor, Biological Psychiatry, University of Southampton and co-director of Memory Assessment and Research Centre, Southern Health Foundation Trust
Clive Holmes is Professor of Biological Psychiatry within Medicine at the University of Southampton with a focus on research on the biological factors that alter the clinical course of Alzheimer’s Disease and other related chronic neurodegenerative conditions but with a focus on the role of inflammation. Professor Clive Holmes was appointed to the Chair of Biological Psychiatry in 2005. He graduated with a first class honours degree in biology from the University of Sussex in 1981 and then went on to study medicine at the University of Leicester; graduating in 1987. He trained in general psychiatry at Guy’s Hospital, London with a two-year additional placement as a visiting research fellow in Neurochemistry at the Institute of Neurology, London. Following this placement, he undertook higher training as a Lecturer in Old Age Psychiatry at the Institute of Psychiatry before completing his PhD on the genetics of the neuropsychiatric features of Alzheimer’s Disease in 2001. He held a post as a Senior Lecturer in Old Age Psychiatry at the University of Southampton before being promoted to his current appointment. He is an honorary consultant in Old Age Psychiatry at Southern Health Foundation Trust.